Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease.
Biomedicines. 2022 Oct 7;10(10):2509. doi: 10.3390/biomedicines10102509.
Biomedicines. 2022.
PMID: 36289772
Free PMC article.
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
Hüttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Vaněčkova I, Malinska H.
Hüttl M, et al.
Int J Mol Sci. 2021 Oct 26;22(21):11513. doi: 10.3390/ijms222111513.
Int J Mol Sci. 2021.
PMID: 34768942
Free PMC article.
Item in Clipboard
Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein.
Malínská H, Hüttl M, Marková I, Miklánková D, Hojná S, Papoušek F, Šilhavý J, Mlejnek P, Zicha J, Hrdlička J, Pravenec M, Vaněčková I.
Malínská H, et al.
Biomedicines. 2022 Aug 24;10(9):2066. doi: 10.3390/biomedicines10092066.
Biomedicines. 2022.
PMID: 36140169
Free PMC article.
Item in Clipboard
Cite
Cite